Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$49700.00
-1000.00 (-1.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-18.9B · quality 58.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$614.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.1%
↓Gross Margin
-100.1%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.6%
FCF CAGR
—
FCF margin
-938.2%
FCF / Net income
3.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.94B · net income $-8.46B · FCF $-27.57B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.94B | $2.94B | $1.78B | $658.2M | $3.72B |
| Net Income | $-8.46B | $-8.46B | $-17.00B | $-26.99B | $-10.60B |
| EBITDA | $-1.93B | $-1.93B | $-13.21B | $-23.50B | $-8.07B |
| EPS | — | — | -1854.00 | -3212.00 | -1457.00 |
| Gross Margin | -100.1% | -100.1% | 98.4% | 88.7% | 89.2% |
| Operating Margin | -965.7% | -965.7% | -1063.6% | -2427.5% | -292.8% |
| Net Margin | -287.8% | -287.8% | -953.3% | -4101.5% | -284.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.50 | 2.43 | 0.09 |
| Current Ratio | 2.02 | 2.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-27.57B | $-27.57B | $-17.98B | $-18.85B | $-7.17B |
| Returns | |||||
| ROE | -13.1% | -13.1% | -52.2% | -612.0% | -34.8% |
| Valuation | |||||
| P/B | 9.54 | 9.54 | 5.74 | 31.92 | 2.30 |
| Growth & Yield | |||||
| Revenue Growth | 64.8% | 64.8% | 170.9% | -82.3% | — |
| EPS Growth | — | — | 42.3% | -120.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1854.00 → n/d
Residual
+13.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.